carmustine

(redirected from Gliadel)
Also found in: Medical.

car·mus·tine

 (kär′mŭs-tēn′)
n.
An antineoplastic drug, C5H9Cl2N3O2, used to treat various malignancies, including Hodgkin and non-Hodgkin lymphomas, melanoma, multiple myeloma, and brain tumors.

[Probably car(bamoylation), transfer of a carbamoyl group to an amino acid (the drug's method of inhibiting certain enzymes) + mustine, an anticancer drug (must(ard) + -ine).]
References in periodicals archive ?
In August 2011, Eisai established Eisai Mexico, which currently markets the anticancer agents Lenvima, Halaven and Gliadel.
In addition to Halaven being launched, the company currently has submitted the anticancer agent Gliadel, the antiepileptic agents Fycompa and Inovelon as well as the antiobesity agent BELVIQ for review.
Over the years, the wafer-based drug delivery technology originally conceived for a general drug delivery tool was developed to become the Gliadel, a wafer licensed by Esai Inc.
85% 1,3-bis-(2-chloroethyl)-1-nitrosourea) conocido comercialmente como Gliadel.
Sanofi-Aventis markets four out of the 25 cytotoxic therapy cancer brands, Eloxatin (oxaliplatin), Taxotere (docetaxel), Gliadel (carmustine) and TS-1 (tegafur + gimeracil + oteracil), which it co-develops with Taiho, making it the current market leader.
Through MGI, Eisai also gains rights to the Gliadel Wafer, a chemotherapy agent, and Dacogen for myelodysplastic syndromes.
None of the patients had resection of recurrent tumor or Gliadel implants.
In addition to Dacogen, MGI PHARMA markets Aloxi and Gliadel, and has five ongoing pivotal programs to drive future growth," said Lonnie Moulder, president and CEO of MGI PHARMA.
The MIT had asked the patent office to grant an SPC for Gliadel which combines two elements, polifeprosan (an excipient) and carmustine (active ingredient) although the marketing of gliadel has been authorised in Germany since August 1999.
Brain Tumour UK ( run by Ella Pybus, originally from Jesmond, Newcastle ( along with the International Brain Tumour Alliance and Samantha Dickson Research Trust, is campaigning for drugs body the National Institute for Health and Clinical Excellence (Nice) to approve chemotherapy drug Temozolomide and Gliadel, an anti-cancer treatment inserted into the brain during surgery.